Yorvipath denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applied a Quantity Limit to Yorvipath — and How to Appeal

Quantity-limit denials for Yorvipath (palopegteriparatide) typically arise when the prescribed supply, dose frequency, or pack size falls outside the parameters Humana's policy has pre-authorized as standard. This can reflect a policy written before the prescriber individualized the regimen for a specific patient, or a mismatch between Humana's approved quantity and the FDA-approved labeled administration schedule. Because Yorvipath is an injectable hormone-replacement therapy that may require individualized titration under the prescriber's supervision, one-size-fits-all quantity limits can conflict with appropriate clinical management.

## Why This Is Appealable

Quantity limits are appealable when the prescribed quantity is consistent with the FDA-approved prescribing label and the patient's individualized clinical need. If the patient's endocrinologist has determined that a specific quantity is required to achieve adequate disease control — and that determination is supported by the chart — the appeal argument is that the quantity limit does not reflect medically appropriate management of this patient. Humana must apply its criteria in a manner consistent with the FDA-approved label; where the label supports the prescribed quantity, the limit is challengeable.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on the denial notice. Request clinical review — not just claims review — of the quantity determination.
• External review (ACA §2719): If the internal appeal fails, escalate to an IRO. The IRO applies an evidence-based standard and will evaluate whether the limit is consistent with the FDA label and recognized guidelines. Standard window is up to four months; expedited review is available for urgent situations.
• Concurrent quantity-limit exception: Many plans have a separate quantity-limit exception process; ask Humana's pharmacy management line whether this pathway is available in parallel.

## Documentation to Gather

1. FDA-approved prescribing label — specifically the section addressing dosing, titration, and administration frequency. This is the primary reference for what quantity is label-consistent. 2. Prescriber's individualized dosing rationale — a clinical note or letter explaining why the prescribed quantity is appropriate for this specific patient, referencing titration status, disease control, and clinical response. 3. Pharmacy records — showing the dispensing history and confirming the requested quantity is consistent with ongoing therapy, not a duplication. 4. Diagnosis and severity documentation — confirming the patient's hypoparathyroidism diagnosis and the clinical context that drives the prescribed regimen. 5. Prior-treatment documentation — showing that dose adjustments were clinically driven and documented.

## Criteria-Mapping Strategy

Obtain Humana's published quantity-limit criteria for Yorvipath. Identify the specific limit that was applied and the specific quantity that was prescribed. In the appeal cover letter, cite the FDA-approved label's dosing language and the prescriber's clinical note explaining the deviation from the default quantity, if any. Where the prescribed quantity falls within the label's authorized range, state that directly and ask Humana to identify the specific policy basis for the limit — placing the burden of justification on the insurer.